Oxford University Department of Psychiatry and Oxford Health Biomedical Research Centre, Oxford, UK.
Oxford Health NHS Foundation Trust, Oxford, UK.
Psychol Med. 2023 Jul;53(10):4799-4810. doi: 10.1017/S0033291722001805. Epub 2022 Jul 29.
Adolescent major depressive disorder (MDD) is associated with disrupted processing of emotional stimuli and difficulties in cognitive reappraisal. Little is known however about how current pharmacotherapies act to modulate the neural mechanisms underlying these key processes. The current study therefore investigated the neural effects of fluoxetine on emotional reactivity and cognitive reappraisal in adolescent depression.
Thirty-one adolescents with MDD were randomised to acute fluoxetine (10 mg) or placebo. Seventeen healthy adolescents were also recruited but did not receive any treatment for ethical reasons. During functional magnetic resonance imaging (fMRI), participants viewed aversive images and were asked to either experience naturally the emotional state elicited ('Maintain') or to reinterpret the content of the pictures to reduce negative affect ('Reappraise'). Significant activations were identified using whole-brain analysis.
No significant group differences were seen when comparing Reappraise and Maintain conditions. However, when compared to healthy controls, depressed adolescents on placebo showed reduced visual activation to aversive pictures irrespective of the condition. The depressed adolescent group on fluoxetine showed the opposite pattern, i.e. increased visuo-cerebellar activity in response to aversive pictures, when compared to depressed adolescents on placebo.
These data suggest that depression in adolescence may be associated with reduced visual processing of aversive imagery and that fluoxetine may act to reduce avoidance of such cues. This could reflect a key mechanism whereby depressed adolescents engage with negative cues previously avoided. Future research combining fMRI with eye-tracking is nonetheless needed to further clarify these effects.
青少年重度抑郁症(MDD)与情绪刺激处理中断和认知重评困难有关。然而,目前对于当前的药物治疗如何调节这些关键过程的神经机制知之甚少。因此,本研究调查了氟西汀对青少年抑郁症情绪反应和认知重评的神经影响。
31 名患有 MDD 的青少年被随机分配接受急性氟西汀(10 毫克)或安慰剂治疗。出于伦理原因,还招募了 17 名健康青少年,但他们没有接受任何治疗。在功能磁共振成像(fMRI)期间,参与者观看了令人不快的图像,并被要求要么自然体验引发的情绪状态(“维持”),要么重新解释图片的内容以减少负面情绪(“重评”)。使用全脑分析确定了显著的激活。
在比较重评和维持条件时,没有发现组间的显著差异。然而,与健康对照组相比,服用安慰剂的抑郁青少年在无论哪种条件下,对不愉快图片的视觉激活都减少了。与服用安慰剂的抑郁青少年相比,服用氟西汀的抑郁青少年在看到不愉快的图片时,表现出相反的模式,即视-小脑活动增加。
这些数据表明,青少年抑郁症可能与不愉快的图像视觉处理减少有关,而氟西汀可能通过减少对这些线索的回避来发挥作用。这可能反映了抑郁青少年以前回避的负面线索的关键机制。然而,未来需要结合 fMRI 和眼动追踪的研究来进一步阐明这些影响。